Caring Brands (NASDAQ:CABR) Stock Price Down 1.8% – Here’s What Happened

Caring Brands, Inc. (NASDAQ:CABR) shares traded down 1.8% during mid-day trading on Tuesday . The company traded as low as $1.34 and last traded at $1.34. 90,915 shares were traded during mid-day trading, an increase of 52% from the average session volume of 59,778 shares. The stock had previously closed at $1.3650.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Caring Brands has a consensus rating of “Sell”.

Caring Brands Stock Up 5.3%

The firm’s 50-day moving average is $1.21. The company has a market capitalization of $12.64 million and a P/E ratio of -2.17. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.62 and a current ratio of 5.66.

Caring Brands (NASDAQ:CABR) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.27) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC acquired a new position in Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent filing with the Securities and Exchange Commission.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.